Valdes-Zayas A, et al. - Experts formulated a study and examined the immunogenicity of a cancer vaccine consisting of the NeuGcGM3 ganglioside combined with the outer membrane protein complex of Neisseria meningitides to form very small size particles. As per their knowledge, this was the first study to indicate the immunogenicity of the NeuGcGM3/VSSP/Montanide ISA 51 vaccine in the adjuvant setting. Additionally, this study determined the functionality of induced anti-NeuGcGM3 antibodies as potential surrogate biomarkers of clinical benefit.